Myocardial Ischemia Related to Common Cancer Therapy—Prevention Insights
Abstract
:1. Introduction
2. Antimetabolites (5-FU, Capecitabine, Gemcitabine)
3. Platinum Compounds (Cisplatin)
4. VEGF/VEGFR Inhibitors (Bevacizumab, Sorafenib, Sunitinib)
5. Radiotherapy
6. Discussion
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5–29. [Google Scholar] [CrossRef] [PubMed]
- De Angelis, R.; Sant, M.; Coleman, M.P.; Francisci, S.; Baili, P.; Pierannunzio, D.; Trama, A.; Visser, O.; Brenner, H.; Ardanaz, E.; et al. Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE--5-a population-based study. Lancet Oncol. 2014, 15, 23–34. [Google Scholar] [CrossRef]
- Han, X.J.; Li, J.Q.; Khannanova, Z.; Li, Y. Optimal management of coronary artery disease in cancer patients. Chronic Dis. Transl. Med. 2019, 5, 221–233. [Google Scholar] [CrossRef] [PubMed]
- Boulet, J.; Pena, J.; Hulten, E.A.; Neilan, T.G.; Dragomir, A.; Freeman, C.; Lambert, C.; Hijal, T.; Nadeau, L.; Brophy, J.M.; et al. Statin Use and Risk of Vascular Events Among Cancer Patients After Radiotherapy to the Thorax, Head, and Neck. J. Am. Heart Assoc. 2019, 8, e005996. [Google Scholar] [CrossRef] [PubMed]
- Zamorano, J.L.; Lancellotti, P.; Rodriguez Munoz, D.; Aboyans, V.; Asteggiano, R.; Galderisi, M.; Habib, G.; Lenihan, D.J.; Lip, G.Y.H.; Lyon, A.R.; et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. Heart J. 2016, 37, 2768–2801. [Google Scholar] [CrossRef]
- Belzile-Dugas, E.; Eisenberg, M.J. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology. J. Am. Heart Assoc. 2021, 10, e021686. [Google Scholar] [CrossRef]
- Min, S.S.; Wierzbicki, A.S. Radiotherapy, chemotherapy and atherosclerosis. Curr. Opin. Cardiol. 2017, 32, 441–447. [Google Scholar] [CrossRef]
- Carlson, L.E.; Watt, G.P.; Tonorezos, E.S.; Chow, E.J.; Yu, A.F.; Woods, M.; Lynch, C.F.; John, E.M.; Mellemkjr, L.; Brooks, J.D.; et al. Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer: The WECARE Study. JACC Cardio Oncol. 2021, 3, 381–392. [Google Scholar] [CrossRef]
- Haugnes, H.S.; Wethal, T.; Aass, N.; Dahl, O.; Klepp, O.; Langberg, C.W.; Wilsgaard, T.; Bremnes, R.M.; Fossa, S.D. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J. Clin. Oncol. 2010, 28, 4649–4657. [Google Scholar] [CrossRef]
- Miura, K.; Kinouchi, M.; Ishida, K.; Fujibuchi, W.; Naitoh, T.; Ogawa, H.; Ando, T.; Yazaki, N.; Watanabe, K.; Haneda, S.; et al. 5-FU metabolism in cancer and orally-administrable 5-FU drugs. Cancers 2010, 2, 1717–1730. [Google Scholar] [CrossRef] [Green Version]
- Sara, J.D.; Kaur, J.; Khodadadi, R.; Rehman, M.; Lobo, R.; Chakrabarti, S.; Herrmann, J.; Lerman, A.; Grothey, A. 5-fluorouracil and cardiotoxicity: A review. Ther. Adv. Med. Oncol. 2018, 10, 1758835918780140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lestuzzi, C.; Vaccher, E.; Talamini, R.; Lleshi, A.; Meneguzzo, N.; Viel, E.; Scalone, S.; Tartuferi, L.; Buonadonna, A.; Ejiofor, L.; et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: An underestimated risk. Ann. Oncol. 2014, 25, 1059–1064. [Google Scholar] [CrossRef]
- Rezkalla, S.; Kloner, R.A.; Ensley, J.; al-Sarraf, M.; Revels, S.; Olivenstein, A.; Bhasin, S.; Kerpel-Fronious, S.; Turi, Z.G. Continuous ambulatory ECG monitoring during fluorouracil therapy: A prospective study. J. Clin. Oncol. 1989, 7, 509–514. [Google Scholar] [CrossRef]
- Ng, M.; Cunningham, D.; Norman, A.R. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur. J. Cancer 2005, 41, 1542–1546. [Google Scholar] [CrossRef] [PubMed]
- Hilmi, M.; Ederhy, S.; Waintraub, X.; Funck-Brentano, C.; Cohen, A.; Vozy, A.; Lebrun-Vignes, B.; Moslehi, J.; Nguyen, L.S.; Salem, J.E. Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. Pharmaceuticals 2020, 13, 325. [Google Scholar] [CrossRef]
- Shiga, T.; Hiraide, M. Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. Curr. Treat Options Oncol. 2020, 21, 27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saif, M.W.; Shah, M.M.; Shah, A.R. Fluoropyrimidine-associated cardiotoxicity: Revisited. Expert Opin. Drug Saf. 2009, 8, 191–202. [Google Scholar] [CrossRef]
- Mosseri, M.; Fingert, H.J.; Varticovski, L.; Chokshi, S.; Isner, J.M. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993, 53, 3028–3033. [Google Scholar]
- Thyss, A.; Gaspard, M.H.; Marsault, R.; Milano, G.; Frelin, C.; Schneider, M. Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann. Oncol. 1992, 3, 88. [Google Scholar] [CrossRef]
- Ozturk, B.; Tacoy, G.; Coskun, U.; Yaman, E.; Sahin, G.; Buyukberber, S.; Yildiz, R.; Kaya, A.O.; Topal, S.; Ozdemir, M.; et al. Gemcitabine-induced acute coronary syndrome: A case report. Med. Princ. Pract. 2009, 18, 76–80. [Google Scholar] [CrossRef]
- Shoemaker, L.K.; Arora, U.; Rocha Lima, C.M. 5-fluorouracil-induced coronary vasospasm. Cancer Control 2004, 11, 46–49. [Google Scholar] [CrossRef] [PubMed]
- Layoun, M.E.; Wickramasinghe, C.D.; Peralta, M.V.; Yang, E.H. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management. Curr. Oncol. Rep. 2016, 18, 35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Polk, A.; Vistisen, K.; Vaage-Nilsen, M.; Nielsen, D.L. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol. Toxicol. 2014, 15, 47. [Google Scholar] [CrossRef] [Green Version]
- Jensen, S.A.; Sorensen, J.B. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother. Pharmacol. 2006, 58, 487–493. [Google Scholar] [CrossRef] [PubMed]
- Kinhult, S.; Albertsson, M.; Eskilsson, J.; Cwikiel, M. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: A scanning microscopy evaluation. Scanning 2001, 23, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Kinhult, S.; Albertsson, M.; Eskilsson, J.; Cwikiel, M. Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol. 2003, 42, 304–308. [Google Scholar] [CrossRef]
- Focaccetti, C.; Bruno, A.; Magnani, E.; Bartolini, D.; Principi, E.; Dallaglio, K.; Bucci, E.O.; Finzi, G.; Sessa, F.; Noonan, D.M.; et al. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS ONE 2015, 10, e0115686. [Google Scholar] [CrossRef]
- Spasojevic, I.; Jelic, S.; Zakrzewska, J.; Bacic, G. Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia. Molecules 2008, 14, 53–67. [Google Scholar] [CrossRef]
- Karakulak, U.N.; Aladag, E.; Maharjan, N.; Ovunc, K. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy. Turk Kardiyol Dern Ars 2016, 44, 71–74. [Google Scholar] [CrossRef] [Green Version]
- Wijesinghe, N.; Thompson, P.I.; McAlister, H. Acute coronary syndrome induced by capecitabine therapy. Heart Lung Circ. 2006, 15, 337–339. [Google Scholar] [CrossRef]
- Yuan, C.; Parekh, H.; Allegra, C.; George, T.J.; Starr, J.S. 5-FU induced cardiotoxicity: Case series and review of the literature. Cardiooncology 2019, 5, 13. [Google Scholar] [CrossRef] [Green Version]
- Bdair, F.M.; Graham, S.P.; Smith, P.F.; Javle, M.M. Gemcitabine and acute myocardial infarction--a case report. Angiology 2006, 57, 367–371. [Google Scholar] [CrossRef] [PubMed]
- Dumontet, C.; Morschhauser, F.; Solal-Celigny, P.; Bouafia, F.; Bourgeois, E.; Thieblemont, C.; Leleu, X.; Hequet, O.; Salles, G.; Coiffier, B. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin’s lymphoma. Br. J. Haematol. 2001, 113, 772–778. [Google Scholar] [CrossRef] [PubMed]
- Kalapura, T.; Krishnamurthy, M.; Reddy, C.V. Acute myocardial infarction following gemcitabine therapy—A case report. Angiology 1999, 50, 1021–1025. [Google Scholar] [CrossRef] [PubMed]
- Farina, A.; Malafronte, C.; Valsecchi, M.A.; Achilli, F. Capecitabine-induced cardiotoxicity: When to suspect? How to manage? A case report. J. Cardiovasc. Med. 2009, 10, 722–726. [Google Scholar] [CrossRef] [PubMed]
- Senturk, T.; Kanat, O.; Evrensel, T.; Aydinlar, A. Capecitabine-induced cardiotoxicity mimicking myocardial infarction. Neth. Heart J. 2009, 17, 277–280. [Google Scholar] [CrossRef]
- Eskilsson, J.; Albertsson, M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol. 1990, 29, 1001–1003. [Google Scholar] [CrossRef]
- Ambrosy, A.P.; Kunz, P.L.; Fisher, G.A.; Witteles, R.M. Capecitabine-induced chest pain relieved by diltiazem. Am. J. Cardiol. 2012, 110, 1623–1626. [Google Scholar] [CrossRef]
- Oleksowicz, L.; Bruckner, H.W. Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. Am. J. Med. 1988, 85, 750–751. [Google Scholar] [CrossRef]
- Senkus, E.; Jassem, J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011, 37, 300–311. [Google Scholar] [CrossRef]
- Clasen, S.C.; Ky, B.; O’Quinn, R.; Giantonio, B.; Teitelbaum, U.; Carver, J.R. Fluoropyrimidine-induced cardiac toxicity: Challenging the current paradigm. J. Gastrointest. Oncol. 2017, 8, 970–979. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chovanec, M.; Abu Zaid, M.; Hanna, N.; El-Kouri, N.; Einhorn, L.H.; Albany, C. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann. Oncol. 2017, 28, 2670–2679. [Google Scholar] [CrossRef] [PubMed]
- Weijl, N.I.; Rutten, M.F.; Zwinderman, A.H.; Keizer, H.J.; Nooy, M.A.; Rosendaal, F.R.; Cleton, F.J.; Osanto, S. Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature. J. Clin. Oncol. 2000, 18, 2169–2178. [Google Scholar] [CrossRef] [PubMed]
- Soultati, A.; Mountzios, G.; Avgerinou, C.; Papaxoinis, G.; Pectasides, D.; Dimopoulos, M.A.; Papadimitriou, C. Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications. Cancer Treat Rev. 2012, 38, 473–483. [Google Scholar] [CrossRef]
- Hanchate, L.P.; Sharma, S.R.; Madyalkar, S. Cisplatin Induced Acute Myocardial Infarction and Dyslipidemia. J. Clin. Diagn. Res. 2017, 11, OD05–OD07. [Google Scholar] [CrossRef]
- Wang, G.; Su, C.; Yin, T. Paclitaxel and platinum-based chemotherapy results in transient dyslipidemia in cancer patients. Mol. Clin. Oncol. 2017, 6, 261–265. [Google Scholar] [CrossRef] [Green Version]
- Meinardi, M.T.; Gietema, J.A.; van der Graaf, W.T.; van Veldhuisen, D.J.; Runne, M.A.; Sluiter, W.J.; de Vries, E.G.; Willemse, P.B.; Mulder, N.H.; van den Berg, M.P.; et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 2000, 18, 1725–1732. [Google Scholar] [CrossRef]
- Haugnes, H.S.; Aass, N.; Fossa, S.D.; Dahl, O.; Klepp, O.; Wist, E.A.; Svartberg, J.; Wilsgaard, T.; Bremnes, R.M. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann. Oncol. 2007, 18, 241–248. [Google Scholar] [CrossRef]
- Moore, R.A.; Adel, N.; Riedel, E.; Bhutani, M.; Feldman, D.R.; Tabbara, N.E.; Soff, G.; Parameswaran, R.; Hassoun, H. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis. J. Clin. Oncol. 2011, 29, 3466–3473. [Google Scholar] [CrossRef]
- Centola, M.; Lucreziotti, S.; Cazzaniga, S.; Salerno-Uriarte, D.; Sponzilli, C.; Carugo, S. A rare case of large intracoronary thrombosis in advanced breast cancer patient treated with epirubicin and cisplatin. J. Cardiovasc. Med. 2016, 17 (Suppl S2), e241–e243. [Google Scholar] [CrossRef]
- Khalid, S.B.; Mahmood, J. Cisplatin induced coronary artery atherosclerosis leading to ST-elevation myocardial infarction: A case report. Circulation 2021, 144, A17234. [Google Scholar] [CrossRef]
- Karabay, K.O.; Yildiz, O.; Aytekin, V. Multiple coronary thrombi with cisplatin. J. Invasive Cardiol. 2014, 26, E18–E20. [Google Scholar] [PubMed]
- Berliner, S.; Rahima, M.; Sidi, Y.; Teplitsky, Y.; Zohar, Y.; Nussbaum, B.; Pinkhas, J. Acute coronary events following cisplatin-based chemotherapy. Cancer Investig. 1990, 8, 583–586. [Google Scholar] [CrossRef] [PubMed]
- Scafa-Udriste, A.; Popa-Fotea, N.M.; Bataila, V.; Calmac, L.; Dorobantu, M. Acute inferior myocardial infarction in a young man with testicular seminoma: A case report. World J. Clin. Cases 2021, 9, 4040–4045. [Google Scholar] [CrossRef] [PubMed]
- Fukuda, M.; Oka, M.; Itoh, N.; Sakamoto, T.; Mori, H.; Hayakawa, A.; Kohno, S. Vasospastic angina likely related to cisplatin-containing chemotherapy and thoracic irradiation for lung cancer. Intern. Med. 1999, 38, 436–438. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rao, A.S.; Kumar, R.; Narayanan, G.S. A rare case of cisplatin-induced acute myocardial infarction in a patient receiving chemoradiation for lung cancer. J. Cancer Res. Ther. 2015, 11, 983–985. [Google Scholar] [CrossRef]
- Somov, P.; Marchak, D.; Matusov, A.; Viller, A.; Shevchenko, Y.; Miminoshvili, A. Spontaneous coronary artery dissection during cisplatin and capecitabine therapy. Ann. Med. Surg. 2019, 45, 1–5. [Google Scholar] [CrossRef]
- Brinkmann, M.; Tallone, E.M.; Wurschmidt, F.; Wulfing, C.; Dieckmann, K.P. Myocardial infarction in a young patient with seminoma during chemotherapy with cisplatinum, etoposide, and bleomycin. Aktuelle Urol. 2021, 52, 54–57. [Google Scholar] [CrossRef]
- Feldman, D.R.; Schaffer, W.L.; Steingart, R.M. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J. Natl. Compr. Cancer Netw. 2012, 10, 537–544. [Google Scholar] [CrossRef] [Green Version]
- Bjerring, A.W.; Fossa, S.D.; Haugnes, H.S.; Nome, R.; Stokke, T.M.; Haugaa, K.H.; Kiserud, C.E.; Edvardsen, T.; Sarvari, S.I. The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: A 30-year follow-up. Eur. Heart J. Cardiovasc. Imaging 2021, 22, 443–450. [Google Scholar] [CrossRef]
- Cameron, A.C.; Touyz, R.M.; Lang, N.N. Vascular Complications of Cancer Chemotherapy. Can. J. Cardiol. 2016, 32, 852–862. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nuver, J.; Smit, A.J.; van der Meer, J.; van den Berg, M.P.; van der Graaf, W.T.; Meinardi, M.T.; Sleijfer, D.T.; Hoekstra, H.J.; van Gessel, A.I.; van Roon, A.M.; et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J. Clin. Oncol. 2005, 23, 9130–9137. [Google Scholar] [CrossRef] [PubMed]
- Sasaki, W.; Wada, H.; Sakakura, K.; Matsuda, J.; Ibe, T.; Hayashi, T.; Ueba, H.; Momomura, S.I.; Fujita, H. Coronary vasospasm induced by cisplatin for seminoma. Clin. Case Rep. 2020, 8, 190–193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rosic, G.; Srejovic, I.; Zivkovic, V.; Selakovic, D.; Joksimovic, J.; Jakovljevic, V. The effects of N-acetylcysteine on cisplatin-induced cardiotoxicity on isolated rat hearts after short-term global ischemia. Toxicol. Rep. 2015, 2, 996–1006. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- El-Awady el, S.E.; Moustafa, Y.M.; Abo-Elmatty, D.M.; Radwan, A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur. J. Pharmacol. 2011, 650, 335–341. [Google Scholar] [CrossRef] [PubMed]
- Knuuti, J.; Wijns, W.; Saraste, A.; Capodanno, D.; Barbato, E.; Funck-Brentano, C.; Prescott, E.; Storey, R.F.; Deaton, C.; Cuisset, T.; et al. Corrigendum to: 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 2020, 41, 4242. [Google Scholar] [CrossRef] [Green Version]
- Song, J.K. Coronary Artery Vasospasm. Korean Circ. J. 2018, 48, 767–777. [Google Scholar] [CrossRef]
- Willemse, P.M.; van der Meer, R.W.; Burggraaf, J.; van Elderen, S.G.; de Kam, M.L.; de Roos, A.; Lamb, H.J.; Osanto, S. Abdominal visceral and subcutaneous fat increase, insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy. Acta Oncol. 2014, 53, 351–360. [Google Scholar] [CrossRef]
- de Haas, E.C.; Altena, R.; Boezen, H.M.; Zwart, N.; Smit, A.J.; Bakker, S.J.; van Roon, A.M.; Postma, A.; Wolffenbuttel, B.H.; Hoekstra, H.J.; et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann. Oncol. 2013, 24, 749–755. [Google Scholar] [CrossRef]
- Westerink, N.L.; Nuver, J.; Lefrandt, J.D.; Vrieling, A.H.; Gietema, J.A.; Walenkamp, A.M. Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle. Crit. Rev. Oncol. Hematol. 2016, 108, 128–136. [Google Scholar] [CrossRef]
- Christensen, J.F.; Bandak, M.; Campbell, A.; Jones, L.W.; Hojman, P. Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship. Acta Oncol. 2015, 54, 592–599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barata, P.C.; Rini, B.I. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J. Clin. 2017, 67, 507–524. [Google Scholar] [CrossRef] [Green Version]
- Tian, W.; Cao, C.; Shu, L.; Wu, F. Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer. Onco Targets Ther. 2020, 13, 12113–12129. [Google Scholar] [CrossRef] [PubMed]
- Mossenta, M.; Busato, D.; Baboci, L.; Cintio, F.D.; Toffoli, G.; Bo, M.D. New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers 2019, 11, 1086. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Capozzi, M.; von Arx, C.; de Divitiis, C.; Ottaiano, A.; Tatangelo, F.; Romano, G.M.; Tafuto, S. Antiangiogenic therapy in pancreatic neuroendocrine tumors. Anticancer Res. 2016, 36, 5025–5030. [Google Scholar] [CrossRef] [Green Version]
- Fudalej, M.M.; Badowska-Kozakiewicz, A.M. Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes. Oncol. Lett. 2021, 21, 417. [Google Scholar] [CrossRef]
- Baraniskin, A.; Buchberger, B.; Pox, C.; Graeven, U.; Holch, J.W.; Schmiegel, W.; Heinemann, V. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Eur. J. Cancer 2019, 106, 37–44. [Google Scholar] [CrossRef]
- Ayoub, N.M.; Jaradat, S.K.; Al-Shami, K.M.; Alkhalifa, A.E. Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Front. Pharmacol. 2022, 13, 838133. [Google Scholar] [CrossRef]
- Touyz, R.M.; Herrmann, S.M.S.; Herrmann, J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J. Am. Soc. Hypertens. 2018, 12, 409–425. [Google Scholar] [CrossRef]
- Jain, R.K.; Duda, D.G.; Clark, J.W.; Loeffler, J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3, 24–40. [Google Scholar] [CrossRef]
- Chen, X.L.; Lei, Y.H.; Liu, C.F.; Yang, Q.F.; Zuo, P.Y.; Liu, C.Y.; Chen, C.Z.; Liu, Y.W. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: A meta-analysis. PLoS ONE 2013, 8, e66721. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gonzalez-Pacheco, F.R.; Deudero, J.J.; Castellanos, M.C.; Castilla, M.A.; Alvarez-Arroyo, M.V.; Yague, S.; Caramelo, C. Mechanisms of endothelial response to oxidative aggression: Protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H1395–H1401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ranpura, V.; Hapani, S.; Chuang, J.; Wu, S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol. 2010, 49, 287–297. [Google Scholar] [CrossRef]
- Scappaticci, F.A.; Skillings, J.R.; Holden, S.N.; Gerber, H.P.; Miller, K.; Kabbinavar, F.; Bergsland, E.; Ngai, J.; Holmgren, E.; Wang, J.; et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl. Cancer Inst. 2007, 99, 1232–1239. [Google Scholar] [CrossRef] [Green Version]
- Totzeck, M.; Mincu, R.I.; Rassaf, T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J. Am. Heart Assoc. 2017, 6, e006278. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Choueiri, T.K.; Schutz, F.A.; Je, Y.; Rosenberg, J.E.; Bellmunt, J. Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. J. Clin. Oncol. 2010, 28, 2280–2285. [Google Scholar] [CrossRef]
- Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 125–134. [Google Scholar] [CrossRef]
- Ueda, K.; Suekane, S.; Ogasawara, N.; Chikui, K.; Suyama, S.; Nakiri, M.; Nishihara, K.; Matsuo, M.; Igawa, T. Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: A case report. J. Med. Case Rep. 2016, 10, 177. [Google Scholar] [CrossRef] [Green Version]
- Zhang, D.; Zhang, X.; Zhao, C. Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: A meta-analysis and systematic review. Onco Targets Ther. 2016, 9, 3695–3704. [Google Scholar] [CrossRef]
- Tebbutt, N.C.; Murphy, F.; Zannino, D.; Wilson, K.; Cummins, M.M.; Abdi, E.; Strickland, A.H.; Lowenthal, R.M.; Marx, G.; Karapetis, C.; et al. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann. Oncol. 2011, 22, 1834–1838. [Google Scholar] [CrossRef]
- Herrmann, J.; Yang, E.H.; Iliescu, C.A.; Cilingiroglu, M.; Charitakis, K.; Hakeem, A.; Toutouzas, K.; Leesar, M.A.; Grines, C.L.; Marmagkiolis, K. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. Circulation 2016, 133, 1272–1289. [Google Scholar] [CrossRef] [PubMed]
- Schmidinger, M.; Zielinski, C.C.; Vogl, U.M.; Bojic, A.; Bojic, M.; Schukro, C.; Ruhsam, M.; Hejna, M.; Schmidinger, H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26, 5204–5212. [Google Scholar] [CrossRef] [PubMed]
- Zhu, X.; Wu, S.; Dahut, W.L.; Parikh, C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am. J. Kidney Dis. 2007, 49, 186–193. [Google Scholar] [CrossRef]
- Zhu, X.; Stergiopoulos, K.; Wu, S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncol. 2009, 48, 9–17. [Google Scholar] [CrossRef] [PubMed]
- Wu, S.; Chen, J.J.; Kudelka, A.; Lu, J.; Zhu, X. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol. 2008, 9, 117–123. [Google Scholar] [CrossRef]
- Pereg, D.; Lishner, M. Bevacizumab treatment for cancer patients with cardiovascular disease: A double edged sword? Eur. Heart J. 2008, 29, 2325–2326. [Google Scholar] [CrossRef] [Green Version]
- Je, Y.; Schutz, F.A.B.; Choueiri, T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009, 10, 967–974. [Google Scholar] [CrossRef]
- Lyon, A.R.; Dent, S.; Stanway, S.; Earl, H.; Brezden-Masley, C.; Cohen-Solal, A.; Tocchetti, C.G.; Moslehi, J.J.; Groarke, J.D.; Bergler-Klein, J.; et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur. J. Heart Fail. 2020, 22, 1945–1960. [Google Scholar] [CrossRef]
- Small, H.Y.; Montezano, A.C.; Rios, F.J.; Savoia, C.; Touyz, R.M. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: Understanding and managing a new syndrome. Can. J. Cardiol. 2014, 30, 534–543. [Google Scholar] [CrossRef]
- Kruzliak, P.; Novak, J.; Novak, M. Vascular endothelial growth factor inhibitor-induced hypertension: From pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am. J. Hypertens. 2014, 27, 3–13. [Google Scholar] [CrossRef]
- Matsuda, Y.; Akita, H.; Terashima, M.; Shiga, N.; Kanazawa, K.; Yokoyama, M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am. Heart J. 2000, 140, 753–759. [Google Scholar] [CrossRef] [PubMed]
- Robinson, E.S.; Khankin, E.V.; Karumanchi, S.A.; Humphreys, B.D. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: Mechanisms and potential use as a biomarker. Semin. Nephrol. 2010, 30, 591–601. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Group, S.R.; Wright, J.T., Jr.; Williamson, J.D.; Whelton, P.K.; Snyder, J.K.; Sink, K.M.; Rocco, M.V.; Reboussin, D.M.; Rahman, M.; Oparil, S.; et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med. 2015, 373, 2103–2116. [Google Scholar] [CrossRef] [PubMed]
- Urbich, C.; Dernbach, E.; Zeiher, A.M.; Dimmeler, S. Double-edged role of statins in angiogenesis signaling. Circ. Res. 2002, 90, 737–744. [Google Scholar] [CrossRef] [Green Version]
- Visseren, F.L.J.; Mach, F.; Smulders, Y.M.; Carballo, D.; Koskinas, K.C.; Back, M.; Benetos, A.; Biffi, A.; Boavida, J.M.; Capodanno, D.; et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2021, 42, 3227–3337. [Google Scholar] [CrossRef]
- Authors/Task Force, M.; Piepoli, M.F.; Hoes, A.W.; Agewall, S.; Albus, C.; Brotons, C.; Catapano, A.L.; Cooney, M.T.; Corra, U.; Cosyns, B.; et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. J. Prev. Cardiol. 2016, 23, NP1–NP96. [Google Scholar] [CrossRef] [Green Version]
- Lewandowski, T.; Szmit, S. Bevacizumab—cardiovascular side effects in daily practice. Oncol. Clin. Pract. 2016, 12, 136–143. [Google Scholar] [CrossRef]
- van Nimwegen, F.A.; Schaapveld, M.; Janus, C.P.; Krol, A.D.; Petersen, E.J.; Raemaekers, J.M.; Kok, W.E.; Aleman, B.M.; van Leeuwen, F.E. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern. Med. 2015, 175, 1007–1017. [Google Scholar] [CrossRef]
- Cheng, Y.J.; Nie, X.Y.; Ji, C.C.; Lin, X.X.; Liu, L.J.; Chen, X.M.; Yao, H.; Wu, S.H. Long-Term Cardiovascular Risk After Radiotherapy in Women With Breast Cancer. J. Am. Heart Assoc. 2017, 6, e005633. [Google Scholar] [CrossRef]
- Barthel, W.; Markwardt, F. Aggregation of blood platelets by adrenaline and its uptake. Biochem. Pharmacol. 1975, 24, 1903–1904. [Google Scholar] [CrossRef]
- Swerdlow, A.J.; Higgins, C.D.; Smith, P.; Cunningham, D.; Hancock, B.W.; Horwich, A.; Hoskin, P.J.; Lister, A.; Radford, J.A.; Rohatiner, A.Z.; et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J. Natl. Cancer Inst. 2007, 99, 206–214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aleman, B.M.; van den Belt-Dusebout, A.W.; De Bruin, M.L.; van’t Veer, M.B.; Baaijens, M.H.; de Boer, J.P.; Hart, A.A.; Klokman, W.J.; Kuenen, M.A.; Ouwens, G.M.; et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007, 109, 1878–1886. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Darby, S.C.; Ewertz, M.; McGale, P.; Bennet, A.M.; Blom-Goldman, U.; Bronnum, D.; Correa, C.; Cutter, D.; Gagliardi, G.; Gigante, B.; et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 2013, 368, 987–998. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hull, M.C.; Morris, C.G.; Pepine, C.J.; Mendenhall, N.P. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003, 290, 2831–2837. [Google Scholar] [CrossRef] [Green Version]
- Mousavi, N.; Nohria, A. Radiation-induced cardiovascular disease. Curr. Treat Options Cardiovasc. Med. 2013, 15, 507–517. [Google Scholar] [CrossRef]
- Jaworski, C.; Mariani, J.A.; Wheeler, G.; Kaye, D.M. Cardiac complications of thoracic irradiation. J. Am. Coll. Cardiol. 2013, 61, 2319–2328. [Google Scholar] [CrossRef] [Green Version]
- Taylor, C.W.; Nisbet, A.; McGale, P.; Darby, S.C. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69, 1484–1495. [Google Scholar] [CrossRef]
- Harris, E.E.; Correa, C.; Hwang, W.T.; Liao, J.; Litt, H.I.; Ferrari, V.A.; Solin, L.J. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J. Clin. Oncol. 2006, 24, 4100–4106. [Google Scholar] [CrossRef]
- Bouillon, K.; Haddy, N.; Delaloge, S.; Garbay, J.R.; Garsi, J.P.; Brindel, P.; Mousannif, A.; Le, M.G.; Labbe, M.; Arriagada, R.; et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. J. Am. Coll. Cardiol. 2011, 57, 445–452. [Google Scholar] [CrossRef]
- Schubert, L.K.; Gondi, V.; Sengbusch, E.; Westerly, D.C.; Soisson, E.T.; Paliwal, B.R.; Mackie, T.R.; Mehta, M.P.; Patel, R.R.; Tome, W.A.; et al. Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. Radiother. Oncol. 2011, 100, 241–246. [Google Scholar] [CrossRef]
- Jagsi, R.; Moran, J.; Marsh, R.; Masi, K.; Griffith, K.A.; Pierce, L.J. Evaluation of four techniques using intensity-modulated radiation therapy for comprehensive locoregional irradiation of breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78, 1594–1603. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martinou, M.; Gaya, A. Cardiac complications after radical radiotherapy. Semin. Oncol. 2013, 40, 178–185. [Google Scholar] [CrossRef] [PubMed]
- Myrehaug, S.; Pintilie, M.; Yun, L.; Crump, M.; Tsang, R.W.; Meyer, R.M.; Sussman, J.; Yu, E.; Hodgson, D.C. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood 2010, 116, 2237–2240. [Google Scholar] [CrossRef] [Green Version]
- Yang, E.H.; Marmagkiolis, K.; Balanescu, D.V.; Hakeem, A.; Donisan, T.; Finch, W.; Virmani, R.; Herrman, J.; Cilingiroglu, M.; Grines, C.L.; et al. Radiation-Induced Vascular Disease-A State-of-the-Art Review. Front. Cardiovasc. Med. 2021, 8, 652761. [Google Scholar] [CrossRef] [PubMed]
- Tukenova, M.; Guibout, C.; Oberlin, O.; Doyon, F.; Mousannif, A.; Haddy, N.; Guerin, S.; Pacquement, H.; Aouba, A.; Hawkins, M.; et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J. Clin. Oncol. 2010, 28, 1308–1315. [Google Scholar] [CrossRef]
- Rademaker, J.; Schoder, H.; Ariaratnam, N.S.; Strauss, H.W.; Yahalom, J.; Steingart, R.; Oeffinger, K.C. Coronary artery disease after radiation therapy for Hodgkin’s lymphoma: Coronary CT angiography findings and calcium scores in nine asymptomatic patients. AJR Am. J. Roentgenol. 2008, 191, 32–37. [Google Scholar] [CrossRef]
- Kupeli, S.; Hazirolan, T.; Varan, A.; Akata, D.; Alehan, D.; Hayran, M.; Besim, A.; Buyukpamukcu, M. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma. J. Clin. Oncol. 2010, 28, 1025–1030. [Google Scholar] [CrossRef]
- Galper, S.L.; Yu, J.B.; Mauch, P.M.; Strasser, J.F.; Silver, B.; Lacasce, A.; Marcus, K.J.; Stevenson, M.A.; Chen, M.H.; Ng, A.K. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011, 117, 412–418. [Google Scholar] [CrossRef] [Green Version]
- Totterman, K.J.; Pesonen, E.; Siltanen, P. Radiation-related chronic heart disease. Chest 1983, 83, 875–878. [Google Scholar] [CrossRef] [Green Version]
- Stewart, F.A.; Heeneman, S.; Te Poele, J.; Kruse, J.; Russell, N.S.; Gijbels, M.; Daemen, M. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-/- mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am. J. Pathol. 2006, 168, 649–658. [Google Scholar] [CrossRef] [Green Version]
- Cuomo, J.R.; Javaheri, S.P.; Sharma, G.K.; Kapoor, D.; Berman, A.E.; Weintraub, N.L. How to prevent and manage radiation-induced coronary artery disease. Heart 2018, 104, 1647–1653. [Google Scholar] [CrossRef] [PubMed]
- Orzan, F.; Brusca, A.; Conte, M.R.; Presbitero, P.; Figliomeni, M.C. Severe coronary artery disease after radiation therapy of the chest and mediastinum: Clinical presentation and treatment. Br. Heart J. 1993, 69, 496–500. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yusuf, S.W.; Sami, S.; Daher, I.N. Radiation-induced heart disease: A clinical update. Cardiol. Res. Pract. 2011, 2011, 317659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taunk, N.K.; Haffty, B.G.; Kostis, J.B.; Goyal, S. Radiation-induced heart disease: Pathologic abnormalities and putative mechanisms. Front. Oncol. 2015, 5, 39. [Google Scholar] [CrossRef] [Green Version]
- Camara Planek, M.I.; Silver, A.J.; Volgman, A.S.; Okwuosa, T.M. Exploratory Review of the Role of Statins, Colchicine, and Aspirin for the Prevention of Radiation-Associated Cardiovascular Disease and Mortality. J. Am. Heart Assoc. 2020, 9, e014668. [Google Scholar] [CrossRef]
- Wei, T.; Cheng, Y. The cardiac toxicity of radiotherapy - a review of characteristics, mechanisms, diagnosis, and prevention. Int. J. Radiat. Biol. 2021, 97, 1333–1340. [Google Scholar] [CrossRef]
- Darby, S.C.; Cutter, D.J.; Boerma, M.; Constine, L.S.; Fajardo, L.F.; Kodama, K.; Mabuchi, K.; Marks, L.B.; Mettler, F.A.; Pierce, L.J.; et al. Radiation-related heart disease: Current knowledge and future prospects. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76, 656–665. [Google Scholar] [CrossRef] [Green Version]
- Yan, Y.; Lu, Z.; Liu, Z.; Luo, W.; Shao, S.; Tan, L.; Ma, X.; Liu, J.; Drokow, E.K.; Ren, J. Dosimetric comparison between three- and four-dimensional computerised tomography radiotherapy for breast cancer. Oncol. Lett. 2019, 18, 1800–1814. [Google Scholar] [CrossRef] [Green Version]
- Darapu, A.; Balakrishnan, R.; Sebastian, P.; Hussain, M.R.; Ravindran, P.; John, S. Is the Deep Inspiration Breath-Hold Technique Superior to the Free Breathing Technique in Cardiac and Lung Sparing while Treating both Left-Sided Post-Mastectomy Chest Wall and Supraclavicular Regions? Case Rep. Oncol. 2017, 10, 37–51. [Google Scholar] [CrossRef]
- Dell’Oro, M.; Giles, E.; Sharkey, A.; Borg, M.; Connell, C.; Bezak, E. A Retrospective Dosimetric Study of Radiotherapy Patients with Left-Sided Breast Cancer; Patient Selection Criteria for Deep Inspiration Breath Hold Technique. Cancers 2019, 11, 259. [Google Scholar] [CrossRef] [Green Version]
- Armenian, S.H.; Lacchetti, C.; Barac, A.; Carver, J.; Constine, L.S.; Denduluri, N.; Dent, S.; Douglas, P.S.; Durand, J.B.; Ewer, M.; et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2017, 35, 893–911. [Google Scholar] [CrossRef] [PubMed]
- Lai, J.; Hu, S.; Luo, Y.; Zheng, R.; Zhu, Q.; Chen, P.; Chi, B.; Zhang, Y.; Zhong, F.; Long, X. Meta-analysis of deep inspiration breath hold (DIBH) versus free breathing (FB) in postoperative radiotherapy for left-side breast cancer. Breast Cancer 2020, 27, 299–307. [Google Scholar] [CrossRef] [PubMed]
- Hjelstuen, M.H.; Mjaaland, I.; Vikstrom, J.; Dybvik, K.I. Radiation during deep inspiration allows loco-regional treatment of left breast and axillary-, supraclavicular- and internal mammary lymph nodes without compromising target coverage or dose restrictions to organs at risk. Acta Oncol. 2012, 51, 333–344. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vikstrom, J.; Hjelstuen, M.H.; Mjaaland, I.; Dybvik, K.I. Cardiac and pulmonary dose reduction for tangentially irradiated breast cancer, utilizing deep inspiration breath-hold with audio-visual guidance, without compromising target coverage. Acta Oncol. 2011, 50, 42–50. [Google Scholar] [CrossRef]
- Shim, J.G.; Kim, J.K.; Park, W.; Seo, J.M.; Hong, C.S.; Song, K.W.; Lim, C.H.; Jung, H.R.; Kim, C.H. Dose-Volume Analysis of Lung and Heart according to Respiration in Breast Cancer Patients Treated with Breast Conserving Surgery. J. Breast Cancer 2012, 15, 105–110. [Google Scholar] [CrossRef] [PubMed]
- Simonetto, C.; Eidemuller, M.; Gaasch, A.; Pazos, M.; Schonecker, S.; Reitz, D.; Kaab, S.; Braun, M.; Harbeck, N.; Niyazi, M.; et al. Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy. Radiother. Oncol. 2019, 131, 202–207. [Google Scholar] [CrossRef] [Green Version]
- Mutter, R.W.; Choi, J.I.; Jimenez, R.B.; Kirova, Y.M.; Fagundes, M.; Haffty, B.G.; Amos, R.A.; Bradley, J.A.; Chen, P.Y.; Ding, X.; et al. Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee. Int. J. Radiat. Oncol. Biol. Phys. 2021, 111, 337–359. [Google Scholar] [CrossRef]
- Wang, H.; Wei, J.; Zheng, Q.; Meng, L.; Xin, Y.; Yin, X.; Jiang, X. Radiation-induced heart disease: A review of classification, mechanism and prevention. Int. J. Biol. Sci. 2019, 15, 2128–2138. [Google Scholar] [CrossRef] [Green Version]
- Tawakol, A.; Fayad, Z.A.; Mogg, R.; Alon, A.; Klimas, M.T.; Dansky, H.; Subramanian, S.S.; Abdelbaky, A.; Rudd, J.H.; Farkouh, M.E.; et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: Results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J. Am. Coll. Cardiol. 2013, 62, 909–917. [Google Scholar] [CrossRef] [Green Version]
- Zheng, G.; Chen, J.; Lin, C.; Huang, X.; Lin, J. Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaques Using Optical Coherence Tomography: A Systematic Review and Meta-Analysis. J. Interv. Cardiol. 2015, 28, 514–522. [Google Scholar] [CrossRef]
- Nissen, S.E.; Nicholls, S.J.; Sipahi, I.; Libby, P.; Raichlen, J.S.; Ballantyne, C.M.; Davignon, J.; Erbel, R.; Fruchart, J.C.; Tardif, J.C.; et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006, 295, 1556–1565. [Google Scholar] [CrossRef] [PubMed]
- Marchio, P.; Guerra-Ojeda, S.; Vila, J.M.; Aldasoro, M.; Victor, V.M.; Mauricio, M.D. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxid. Med. Cell. Longev. 2019, 2019, 8563845. [Google Scholar] [CrossRef] [PubMed]
- Ostrau, C.; Hulsenbeck, J.; Herzog, M.; Schad, A.; Torzewski, M.; Lackner, K.J.; Fritz, G. Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo. Radiother. Oncol. 2009, 92, 492–499. [Google Scholar] [CrossRef] [PubMed]
- Doi, H.; Matsumoto, S.; Odawara, S.; Shikata, T.; Kitajima, K.; Tanooka, M.; Takada, Y.; Tsujimura, T.; Kamikonya, N.; Hirota, S. Pravastatin reduces radiation-induced damage in normal tissues. Exp. Ther. Med. 2017, 13, 1765–1772. [Google Scholar] [CrossRef] [Green Version]
- Yang, H.; Huang, F.; Tao, Y.; Zhao, X.; Liao, L.; Tao, X. Simvastatin ameliorates ionizing radiation-induced apoptosis in the thymus by activating the AKT/sirtuin 1 pathway in mice. Int. J. Mol. Med. 2017, 40, 762–770. [Google Scholar] [CrossRef] [Green Version]
- Ran, X.Z.; Ran, X.; Zong, Z.W.; Liu, D.Q.; Xiang, G.M.; Su, Y.P.; Zheng, H.E. Protective effect of atorvastatin on radiation-induced vascular endothelial cell injury in vitro. J. Radiat. Res. 2010, 51, 527–533. [Google Scholar] [CrossRef]
- Zhang, K.; He, X.; Zhou, Y.; Gao, L.; Qi, Z.; Chen, J.; Gao, X. Atorvastatin Ameliorates Radiation-Induced Cardiac Fibrosis in Rats. Radiat. Res. 2015, 184, 611–620. [Google Scholar] [CrossRef]
- Hoving, S.; Heeneman, S.; Gijbels, M.J.; te Poele, J.A.; Pol, J.F.; Gabriels, K.; Russell, N.S.; Daemen, M.J.; Stewart, F.A. Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice. Radiother. Oncol. 2011, 101, 100–108. [Google Scholar] [CrossRef]
- Nubel, T.; Damrot, J.; Roos, W.P.; Kaina, B.; Fritz, G. Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin. Cancer Res. 2006, 12, 933–939. [Google Scholar] [CrossRef] [Green Version]
- Lenarczyk, M.; Su, J.; Haworth, S.T.; Komorowski, R.; Fish, B.L.; Migrino, R.Q.; Harmann, L.; Hopewell, J.W.; Kronenberg, A.; Patel, S.; et al. Simvastatin mitigates increases in risk factors for and the occurrence of cardiac disease following 10 Gy total body irradiation. Pharmacol. Res. Perspect. 2015, 3, e00145. [Google Scholar] [CrossRef]
- Gaugler, M.H.; Vereycken-Holler, V.; Squiban, C.; Vandamme, M.; Vozenin-Brotons, M.C.; Benderitter, M. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat. Res. 2005, 163, 479–487. [Google Scholar] [CrossRef] [PubMed]
- Holler, V.; Buard, V.; Gaugler, M.H.; Guipaud, O.; Baudelin, C.; Sache, A.; Perez Mdel, R.; Squiban, C.; Tamarat, R.; Milliat, F.; et al. Pravastatin limits radiation-induced vascular dysfunction in the skin. J. Invest. Dermatol. 2009, 129, 1280–1291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Addison, D.; Lawler, P.R.; Emami, H.; Janjua, S.A.; Staziaki, P.V.; Hallett, T.R.; Hennessy, O.; Lee, H.; Szilveszter, B.; Lu, M.; et al. Incidental Statin Use and the Risk of Stroke or Transient Ischemic Attack after Radiotherapy for Head and Neck Cancer. J. Stroke 2018, 20, 71–79. [Google Scholar] [CrossRef] [PubMed]
- Hoving, S.; Heeneman, S.; Gijbels, M.J.; te Poele, J.A.; Bolla, M.; Pol, J.F.; Simons, M.Y.; Russell, N.S.; Daemen, M.J.; Stewart, F.A. NO-donating aspirin and aspirin partially inhibit age-related atherosclerosis but not radiation-induced atherosclerosis in ApoE null mice. PLoS ONE 2010, 5, e12874. [Google Scholar] [CrossRef] [Green Version]
- Elwood, P.C.; Morgan, G.; Delon, C.; Protty, M.; Galante, J.; Pickering, J.; Watkins, J.; Weightman, A.; Morris, D. Aspirin and cancer survival: A systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers. Ecancermedicalscience 2021, 15, 1258. [Google Scholar] [CrossRef]
- Ferrari, R.; Fox, K. Insight into the mode of action of ACE inhibition in coronary artery disease: The ultimate ‘EUROPA’ story. Drugs 2009, 69, 265–277. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, B.; Drexler, H.; Schieffer, B. Therapeutic effects of angiotensin (AT1) receptor antagonists: Potential contribution of mechanisms other than AT1 receptor blockade. Am. J. Cardiovasc. Drugs 2004, 4, 361–368. [Google Scholar] [CrossRef]
- Wu, R.; Zeng, Y. Does angiotensin II-aldosterone have a role in radiation-induced heart disease? Med. Hypotheses 2009, 72, 263–266. [Google Scholar] [CrossRef]
- van der Veen, S.J.; Ghobadi, G.; de Boer, R.A.; Faber, H.; Cannon, M.V.; Nagle, P.W.; Brandenburg, S.; Langendijk, J.A.; van Luijk, P.; Coppes, R.P. ACE inhibition attenuates radiation-induced cardiopulmonary damage. Radiother. Oncol. 2015, 114, 96–103. [Google Scholar] [CrossRef] [Green Version]
- Wei, J.; Xu, H.; Liu, Y.; Li, B.; Zhou, F. Effect of captopril on radiation-induced TGF-beta1 secretion in EA.Hy926 human umbilical vein endothelial cells. Oncotarget 2017, 8, 20842–20850. [Google Scholar] [CrossRef] [Green Version]
- Charrier, S.; Michaud, A.; Badaoui, S.; Giroux, S.; Ezan, E.; Sainteny, F.; Corvol, P.; Vainchenker, W. Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 2004, 104, 978–985. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ghosh, S.N.; Zhang, R.; Fish, B.L.; Semenenko, V.A.; Li, X.A.; Moulder, J.E.; Jacobs, E.R.; Medhora, M. Renin-Angiotensin system suppression mitigates experimental radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75, 1528–1536. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Molteni, A.; Wolfe, L.F.; Ward, W.F.; Ts’ao, C.H.; Molteni, L.B.; Veno, P.; Fish, B.L.; Taylor, J.M.; Quintanilla, N.; Herndon, B.; et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr. Pharm. Des. 2007, 13, 1307–1316. [Google Scholar] [CrossRef]
- Deftereos, S.; Giannopoulos, G.; Papoutsidakis, N.; Panagopoulou, V.; Kossyvakis, C.; Raisakis, K.; Cleman, M.W.; Stefanadis, C. Colchicine and the heart: Pushing the envelope. J. Am. Coll. Cardiol. 2013, 62, 1817–1825. [Google Scholar] [CrossRef] [Green Version]
- Nidorf, S.M.; Eikelboom, J.W.; Budgeon, C.A.; Thompson, P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 2013, 61, 404–410. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kofler, T.; Kurmann, R.; Lehnick, D.; Cioffi, G.M.; Chandran, S.; Attinger-Toller, A.; Toggweiler, S.; Kobza, R.; Moccetti, F.; Cuculi, F.; et al. Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials. J. Am. Heart Assoc. 2021, 10, e021198. [Google Scholar] [CrossRef]
- O’Herron, T.; Lafferty, J. Prophylactic use of colchicine in preventing radiation induced coronary artery disease. Med. Hypotheses 2018, 111, 58–60. [Google Scholar] [CrossRef]
- Nidorf, S.M.; Thompson, P.L. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Clin. Ther. 2019, 41, 41–48. [Google Scholar] [CrossRef] [Green Version]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Rottenberg, S.; Disler, C.; Perego, P. The rediscovery of platinum-based cancer therapy. Nat. Rev. Cancer 2021, 21, 37–50. [Google Scholar] [CrossRef]
- Meadows, K.L.; Hurwitz, H.I. Anti-VEGF therapies in the clinic. Cold Spring Harb. Perspect. Med. 2012, 2, a006577. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ewer, M.S.; Benjamin, R.S.; Yeh, E.T.H. Cardiac complications of cancer treatment. In Cancer Medicine; Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Bast, J.R.C., Gansler, T.S., Holland, J.F., Frei, I.E., Eds.; BC Decker Inc.: Hamilton, ON, Canada, 2003. [Google Scholar]
- Christensen, S.; Van der Roest, B.; Besselink, N.; Janssen, R.; Boymans, S.; Martens, J.W.M.; Yaspo, M.L.; Priestley, P.; Kuijk, E.; Cuppen, E.; et al. 5-Fluorouracil treatment induces characteristic T>G mutations in human cancer. Nat. Commun. 2019, 10, 4571. [Google Scholar] [CrossRef] [Green Version]
- Lukasiewicz, S.; Czeczelewski, M.; Forma, A.; Baj, J.; Sitarz, R.; Stanislawek, A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers 2021, 13, 4287. [Google Scholar] [CrossRef] [PubMed]
- Cardinale, D.; Iacopo, F.; Cipolla, C.M. Cardiotoxicity of Anthracyclines. Front. Cardiovasc. Med. 2020, 7, 26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cardinale, D.; Colombo, A.; Bacchiani, G.; Tedeschi, I.; Meroni, C.A.; Veglia, F.; Civelli, M.; Lamantia, G.; Colombo, N.; Curigliano, G.; et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015, 131, 1981–1988. [Google Scholar] [CrossRef] [Green Version]
- Wolf, M.B.; Baynes, J.W. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim. Biophys. Acta 2006, 1760, 267–271. [Google Scholar] [CrossRef]
- Wojcik, T.; Buczek, E.; Majzner, K.; Kolodziejczyk, A.; Miszczyk, J.; Kaczara, P.; Kwiatek, W.; Baranska, M.; Szymonski, M.; Chlopicki, S. Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells. Toxicol. In Vitro 2015, 29, 512–521. [Google Scholar] [CrossRef]
- Murata, T.; Yamawaki, H.; Hori, M.; Sato, K.; Ozaki, H.; Karaki, H. Chronic vascular toxicity of doxorubicin in an organ-cultured artery. Br. J. Pharmacol. 2001, 132, 1365–1373. [Google Scholar] [CrossRef] [Green Version]
- Eckman, D.M.; Stacey, R.B.; Rowe, R.; D’Agostino, R., Jr.; Kock, N.D.; Sane, D.C.; Torti, F.M.; Yeboah, J.; Workman, S.; Lane, K.S.; et al. Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness. PLoS ONE 2013, 8, e57554. [Google Scholar] [CrossRef] [Green Version]
- Galan-Arriola, C.; Vilchez-Tschischke, J.P.; Lobo, M.; Lopez, G.J.; de Molina-Iracheta, A.; Perez-Martinez, C.; Villena-Gutierrez, R.; Macias, A.; Diaz-Rengifo, I.A.; Oliver, E.; et al. Coronary microcirculation damage in anthracycline cardiotoxicity. Cardiovasc. Res. 2022, 118, 531–541. [Google Scholar] [CrossRef]
- Laursen, A.H.; Elming, M.B.; Ripa, R.S.; Hasbak, P.; Kjaer, A.; Kober, L.; Marott, J.L.; Thune, J.J.; Hutchings, M. Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. J. Nucl. Cardiol. 2020, 27, 1698–1707. [Google Scholar] [CrossRef] [PubMed]
- Kirresh, A.; White, L.; Mitchell, A.; Ahmad, S.; Obika, B.; Davis, S.; Ahmad, M.; Candilio, L. Radiation-induced coronary artery disease: A difficult clinical conundrum. Clin. Med. 2022, 22, 251–256. [Google Scholar] [CrossRef] [PubMed]
- Herrmann, J.; Lenihan, D.; Armenian, S.; Barac, A.; Blaes, A.; Cardinale, D.; Carver, J.; Dent, S.; Ky, B.; Lyon, A.R.; et al. Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement. Eur. Heart J. 2022, 43, 280–299. [Google Scholar] [CrossRef] [PubMed]
Drug | Mechanism | Intervention | References |
---|---|---|---|
Antimetabolites (5-FU, Capecitabine, Gemcitabine) | Coronary artery spasm Intravascular thrombosis Endothelial injury | Immediate discontinuation of the drug Calcium channel blockers Long-acting nitrates Short-acting nitrates (on demand) Low-dose aspirin Dalteparin b Probucol b | [25,26,31,35,36,37,38,39,41] |
Platinum Compounds (Cisplatin) | Intravascular thrombosis Coronary artery spasm Coronary artery dissection Endothelial injury Accelerated atherosclerosis Proatherogenic dyslipidemia Hypertension Insulin resistance | Decreased dose or discontinuation of the drug Calcium channel blockers Long-acting nitrates Low-dose aspirin a Statins a N-Acetyl-l-cysteine b Acetyl-carnitine b α-lipoic acid b Silymarin b | [53,56,64,65,67] |
VEGF/VEGFR inhibitors (Bevacizumab, Sorafenib, Sunitinib) | Intravascular thrombosis Endothelial injury Hypertension | RAS inhibitors Calcium channel blockers (only DHP) Beta-blockers (only carvedilol) Diuretics Long-acting nitrates Statins Low-dose aspirin a | [79,84,90,96,100,101,102,104,106,107] |
Radiotherapy | Accelerated atherosclerosis Endothelial injury Plaque rupture Intravascular thrombosis | Radiation dose reduction Statins RAS inhibitors b Low-dose aspirin a Colchicine b | [135,138,139,140,141,142,143,144,145,146,147] [4,158,159,160,161,162,163] [135,164,165] [169,170,171,172,173] [135,177,178] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Badescu, M.C.; Badulescu, O.V.; Scripcariu, D.V.; Butnariu, L.I.; Bararu-Bojan, I.; Popescu, D.; Ciocoiu, M.; Gorduza, E.V.; Costache, I.I.; Rezus, E.; et al. Myocardial Ischemia Related to Common Cancer Therapy—Prevention Insights. Life 2022, 12, 1034. https://doi.org/10.3390/life12071034
Badescu MC, Badulescu OV, Scripcariu DV, Butnariu LI, Bararu-Bojan I, Popescu D, Ciocoiu M, Gorduza EV, Costache II, Rezus E, et al. Myocardial Ischemia Related to Common Cancer Therapy—Prevention Insights. Life. 2022; 12(7):1034. https://doi.org/10.3390/life12071034
Chicago/Turabian StyleBadescu, Minerva Codruta, Oana Viola Badulescu, Dragos Viorel Scripcariu, Lăcrămioara Ionela Butnariu, Iris Bararu-Bojan, Diana Popescu, Manuela Ciocoiu, Eusebiu Vlad Gorduza, Irina Iuliana Costache, Elena Rezus, and et al. 2022. "Myocardial Ischemia Related to Common Cancer Therapy—Prevention Insights" Life 12, no. 7: 1034. https://doi.org/10.3390/life12071034